# Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics

> **NCT04585009** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 56 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK3923868
- **DRUG:** Matching placebo
- **DEVICE:** Monodose RS01

## Key facts

- **NCT ID:** NCT04585009
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-12
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-06-16
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585009, "Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04585009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*